MarketPeel
Insider Trading Intelligence
ED

Earl Martin Douglas

ALLO
SVP, GENERAL COUNSEL · ALLOGENE THERAPEUTICS, INC. · CIK 0001362155
FILING MIX · LIFETIME75%/25%
BUYS
9
SELLS
3
TOTAL VALUE
$130.1K
COMPANIES
1
ACTIVE SINCE
Aug 2023
HOLDINGS NOW
152,480
AVG SELL PX
$2.26
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by Earl Martin Douglas, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+100.00%-10.50%+0.49%-10.99%-10.99%
14d2+0.00%+42.78%+0.24%+42.54%+42.54%
30d2+0.00%+25.43%-1.97%+27.40%+27.40%
60d2+50.00%+9.42%-10.46%+19.88%+19.88%
90d2+50.00%+8.93%-1.10%+10.03%+10.03%
180d2(1 pending)+100.00%-35.33%+4.32%-39.65%-39.65%
1y2(1 pending)+0.00%+4.19%+15.70%-11.51%-11.51%
2y2(2 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ALLO · 152,480 shares · as of Feb 2, 2026
0240,214480,427720,641960,854202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 9 buys / 3 sellsCOVERAGE · 11 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
539,072539,072Feb 2, 2026Feb 4, 2026View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
SVP, General Counsel
22,900$1.76$40.3K564,948Feb 2, 2026Feb 4, 2026View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
152,480152,480Feb 2, 2026Feb 4, 2026View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
SVP, General Counsel
6,404$1.71$11.0K587,848Feb 3, 2025Feb 5, 2025View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
512,370512,370Jan 24, 2025Jan 28, 2025View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
144,928594,252Jan 24, 2025Jan 28, 2025View →
ALLO
ALLOGENE THERAPEUTICS, INC.
SALE
SVP, General Counsel
28,310$2.79$78.8K449,324Aug 21, 2024Aug 23, 2024View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
41,800477,634Jan 25, 2024Jan 31, 2024View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
147,778147,778Jan 25, 2024Jan 31, 2024View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
960,854960,854Aug 14, 2023Aug 17, 2023View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
326,876435,834Aug 14, 2023Aug 17, 2023View →
ALLO
ALLOGENE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
108,958108,958Aug 14, 2023Aug 17, 2023View →
Other insiders · ALLO
Loading peer insiders…
About this filer
CIK 0001362155
ROLE
SVP, General Counsel
PRIMARY
ALLO
COMPANIES
1
ACTIVE SINCE
Aug 2023
MARKETPEEL · /INSIDER/0001362155DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback